Header Logo

Connection

Gabriel Pardo to Antibodies, Monoclonal, Humanized

This is a "connection" page, showing publications Gabriel Pardo has written about Antibodies, Monoclonal, Humanized.
  1. Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data. J Manag Care Spec Pharm. 2021 May; 27(5):639-649.
    View in: PubMed
    Score: 0.685
  2. Safety evaluation of shorter infusion for ocrelizumab in a substudy of the Phase IIIb CHORDS trial. Ann Clin Transl Neurol. 2021 03; 8(3):711-715.
    View in: PubMed
    Score: 0.171
  3. Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis. J Neurol Sci. 2014 Jun 15; 341(1-2):22-7.
    View in: PubMed
    Score: 0.106
  4. Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis. Mult Scler Relat Disord. 2020 Nov; 46:102454.
    View in: PubMed
    Score: 0.041
  5. Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223. J Neurol. 2020 Nov; 267(11):3343-3353.
    View in: PubMed
    Score: 0.041
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.